http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 20 Jul 2026 07:04:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+Jul+20/26786897.html si-local-file:///var/storage/secattach/20260720/26786897.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+Jul+20/26786897.html Mon, 20 Jul 2026 07:04:00 -0400 CANF CANF O.05892622 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+Jul+20/26786897.html si-local-file:///var/storage/secattach/20260720/26786897.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+Jul+20/26786897.html Mon, 20 Jul 2026 07:04:00 -0400 CANF CANF O.05892622 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+Jul+20/26786897.html si-local-file:///var/storage/secattach/20260720/26786897.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+Jul+20/26786897.html Mon, 20 Jul 2026 07:04:00 -0400 CANF CANF O.05892622 http://www.streetinsider.com/FDA/Can-Fite+pancreatic+cancer+drug+data+accepted+for+ESMO+2026+presentation/26786822.html <p>Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) announced that an abstract from its Phase 2a study of Namodenoson in patients with advanced pancreatic ductal adenocarcinoma (PDAC) has been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2026.</p> <p>The abstract, titled "Durable Disease Stabilization with Namodenoson in Advanced Pancreatic Adenocarcinoma: Results from a Phase 2a Study," covers a study of oral Namodenoson in patients with advanced pancreatic cancer who had progressed following prior standard therapies. According to the company, the study met its primary safety endpoint and showed survival outcomes along with disease stabilization. One patient http://www.streetinsider.com/FDA/Can-Fite+pancreatic+cancer+drug+data+accepted+for+ESMO+2026+presentation/26786822.html Mon, 20 Jul 2026 07:00:18 -0400 CANF CFBI O.05892622 http://www.streetinsider.com/FDA/Can-Fite+pancreatic+cancer+drug+data+accepted+for+ESMO+2026+presentation/26786822.html <p>Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) announced that an abstract from its Phase 2a study of Namodenoson in patients with advanced pancreatic ductal adenocarcinoma (PDAC) has been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2026.</p> <p>The abstract, titled "Durable Disease Stabilization with Namodenoson in Advanced Pancreatic Adenocarcinoma: Results from a Phase 2a Study," covers a study of oral Namodenoson in patients with advanced pancreatic cancer who had progressed following prior standard therapies. According to the company, the study met its primary safety endpoint and showed survival outcomes along with disease stabilization. One patient http://www.streetinsider.com/FDA/Can-Fite+pancreatic+cancer+drug+data+accepted+for+ESMO+2026+presentation/26786822.html Mon, 20 Jul 2026 07:00:18 -0400 CANF CFBI O.05892622 http://www.streetinsider.com/FDA/Can-Fite+pancreatic+cancer+drug+data+accepted+for+ESMO+2026+presentation/26786822.html <p>Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) announced that an abstract from its Phase 2a study of Namodenoson in patients with advanced pancreatic ductal adenocarcinoma (PDAC) has been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2026.</p> <p>The abstract, titled "Durable Disease Stabilization with Namodenoson in Advanced Pancreatic Adenocarcinoma: Results from a Phase 2a Study," covers a study of oral Namodenoson in patients with advanced pancreatic cancer who had progressed following prior standard therapies. According to the company, the study met its primary safety endpoint and showed survival outcomes along with disease stabilization. One patient http://www.streetinsider.com/FDA/Can-Fite+pancreatic+cancer+drug+data+accepted+for+ESMO+2026+presentation/26786822.html Mon, 20 Jul 2026 07:00:18 -0400 CANF CFBI O.05892622 http://www.streetinsider.com/Press+Releases/Can-Fite+Positive+Phase+2a+Pancreatic+Cancer+Study+Data+Accepted+for+Presentation+at+ESMO+Congress+2026%2C+One+of+the+World%26apos%3Bs+Premier+Scientific+Meetings+in+Oncology/26786777.html <p align="center"><i>Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months</i></p> <p align="justify">Ramat Gan, Israel, July 20, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ecGmRucGvgQw_lE8ggC3AtwdoLSsmzZMrvY98eDy9CL7-oZ0rRCR5Ig3DCCRYFStYQykbzv3zi67TJC79gANbtNXzEZGt2vseCkyKWdyeqQ=" rel="nofollow" target="_blank">Can-Fite BioPharma</a> Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that an abstract highlighting positive results from its Phase 2a study of Namodenoson in patients with advanced pancreatic ductal adenocarcinoma (PDAC), has been accepted for poster presentation at the European Society http://www.streetinsider.com/Press+Releases/Can-Fite+Positive+Phase+2a+Pancreatic+Cancer+Study+Data+Accepted+for+Presentation+at+ESMO+Congress+2026%2C+One+of+the+World%26apos%3Bs+Premier+Scientific+Meetings+in+Oncology/26786777.html Mon, 20 Jul 2026 07:00:00 -0400 CANF CANF CFBI O.05892622 http://www.streetinsider.com/Press+Releases/Can-Fite+Positive+Phase+2a+Pancreatic+Cancer+Study+Data+Accepted+for+Presentation+at+ESMO+Congress+2026%2C+One+of+the+World%26apos%3Bs+Premier+Scientific+Meetings+in+Oncology/26786777.html <p align="center"><i>Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months</i></p> <p align="justify">Ramat Gan, Israel, July 20, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ecGmRucGvgQw_lE8ggC3AtwdoLSsmzZMrvY98eDy9CL7-oZ0rRCR5Ig3DCCRYFStYQykbzv3zi67TJC79gANbtNXzEZGt2vseCkyKWdyeqQ=" rel="nofollow" target="_blank">Can-Fite BioPharma</a> Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that an abstract highlighting positive results from its Phase 2a study of Namodenoson in patients with advanced pancreatic ductal adenocarcinoma (PDAC), has been accepted for poster presentation at the European Society http://www.streetinsider.com/Press+Releases/Can-Fite+Positive+Phase+2a+Pancreatic+Cancer+Study+Data+Accepted+for+Presentation+at+ESMO+Congress+2026%2C+One+of+the+World%26apos%3Bs+Premier+Scientific+Meetings+in+Oncology/26786777.html Mon, 20 Jul 2026 07:00:00 -0400 CANF CANF CFBI O.05892622 http://www.streetinsider.com/Press+Releases/Can-Fite+Positive+Phase+2a+Pancreatic+Cancer+Study+Data+Accepted+for+Presentation+at+ESMO+Congress+2026%2C+One+of+the+World%26apos%3Bs+Premier+Scientific+Meetings+in+Oncology/26786777.html <p align="center"><i>Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months</i></p> <p align="justify">Ramat Gan, Israel, July 20, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ecGmRucGvgQw_lE8ggC3AtwdoLSsmzZMrvY98eDy9CL7-oZ0rRCR5Ig3DCCRYFStYQykbzv3zi67TJC79gANbtNXzEZGt2vseCkyKWdyeqQ=" rel="nofollow" target="_blank">Can-Fite BioPharma</a> Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that an abstract highlighting positive results from its Phase 2a study of Namodenoson in patients with advanced pancreatic ductal adenocarcinoma (PDAC), has been accepted for poster presentation at the European Society http://www.streetinsider.com/Press+Releases/Can-Fite+Positive+Phase+2a+Pancreatic+Cancer+Study+Data+Accepted+for+Presentation+at+ESMO+Congress+2026%2C+One+of+the+World%26apos%3Bs+Premier+Scientific+Meetings+in+Oncology/26786777.html Mon, 20 Jul 2026 07:00:00 -0400 CANF CANF CFBI O.05892622 http://www.streetinsider.com/Press+Releases/Can-Fite+Positive+Phase+2a+Pancreatic+Cancer+Study+Data+Accepted+for+Presentation+at+ESMO+Congress+2026%2C+One+of+the+World%26apos%3Bs+Premier+Scientific+Meetings+in+Oncology/26786777.html <p align="center"><i>Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months</i></p> <p align="justify">Ramat Gan, Israel, July 20, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ecGmRucGvgQw_lE8ggC3AtwdoLSsmzZMrvY98eDy9CL7-oZ0rRCR5Ig3DCCRYFStYQykbzv3zi67TJC79gANbtNXzEZGt2vseCkyKWdyeqQ=" rel="nofollow" target="_blank">Can-Fite BioPharma</a> Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that an abstract highlighting positive results from its Phase 2a study of Namodenoson in patients with advanced pancreatic ductal adenocarcinoma (PDAC), has been accepted for poster presentation at the European Society http://www.streetinsider.com/Press+Releases/Can-Fite+Positive+Phase+2a+Pancreatic+Cancer+Study+Data+Accepted+for+Presentation+at+ESMO+Congress+2026%2C+One+of+the+World%26apos%3Bs+Premier+Scientific+Meetings+in+Oncology/26786777.html Mon, 20 Jul 2026 07:00:00 -0400 CANF CANF CFBI O.05892622 http://www.streetinsider.com/Globe+Newswire/Can-Fite+Positive+Phase+2a+Pancreatic+Cancer+Study+Data+Accepted+for+Presentation+at+ESMO+Congress+2026%2C+One+of+the+World%26apos%3Bs+Premier+Scientific+Meetings+in+Oncology/26786777.html <p align="center"><i>Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months</i></p> <p align="justify">Ramat Gan, Israel, July 20, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ecGmRucGvgQw_lE8ggC3AtwdoLSsmzZMrvY98eDy9CL7-oZ0rRCR5Ig3DCCRYFStYQykbzv3zi67TJC79gANbtNXzEZGt2vseCkyKWdyeqQ=" rel="nofollow" target="_blank">Can-Fite BioPharma</a> Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that an abstract highlighting positive results from its Phase 2a study of Namodenoson in patients with advanced pancreatic ductal adenocarcinoma (PDAC), has been accepted for poster presentation at the European Society http://www.streetinsider.com/Globe+Newswire/Can-Fite+Positive+Phase+2a+Pancreatic+Cancer+Study+Data+Accepted+for+Presentation+at+ESMO+Congress+2026%2C+One+of+the+World%26apos%3Bs+Premier+Scientific+Meetings+in+Oncology/26786777.html Mon, 20 Jul 2026 07:00:00 -0400 CANF CANF CFBI O.05892622 http://www.streetinsider.com/Globe+Newswire/Can-Fite+Positive+Phase+2a+Pancreatic+Cancer+Study+Data+Accepted+for+Presentation+at+ESMO+Congress+2026%2C+One+of+the+World%26apos%3Bs+Premier+Scientific+Meetings+in+Oncology/26786777.html <p align="center"><i>Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months</i></p> <p align="justify">Ramat Gan, Israel, July 20, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ecGmRucGvgQw_lE8ggC3AtwdoLSsmzZMrvY98eDy9CL7-oZ0rRCR5Ig3DCCRYFStYQykbzv3zi67TJC79gANbtNXzEZGt2vseCkyKWdyeqQ=" rel="nofollow" target="_blank">Can-Fite BioPharma</a> Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that an abstract highlighting positive results from its Phase 2a study of Namodenoson in patients with advanced pancreatic ductal adenocarcinoma (PDAC), has been accepted for poster presentation at the European Society http://www.streetinsider.com/Globe+Newswire/Can-Fite+Positive+Phase+2a+Pancreatic+Cancer+Study+Data+Accepted+for+Presentation+at+ESMO+Congress+2026%2C+One+of+the+World%26apos%3Bs+Premier+Scientific+Meetings+in+Oncology/26786777.html Mon, 20 Jul 2026 07:00:00 -0400 CANF CANF CFBI O.05892622 http://www.streetinsider.com/Globe+Newswire/Can-Fite+Positive+Phase+2a+Pancreatic+Cancer+Study+Data+Accepted+for+Presentation+at+ESMO+Congress+2026%2C+One+of+the+World%26apos%3Bs+Premier+Scientific+Meetings+in+Oncology/26786777.html <p align="center"><i>Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months</i></p> <p align="justify">Ramat Gan, Israel, July 20, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ecGmRucGvgQw_lE8ggC3AtwdoLSsmzZMrvY98eDy9CL7-oZ0rRCR5Ig3DCCRYFStYQykbzv3zi67TJC79gANbtNXzEZGt2vseCkyKWdyeqQ=" rel="nofollow" target="_blank">Can-Fite BioPharma</a> Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that an abstract highlighting positive results from its Phase 2a study of Namodenoson in patients with advanced pancreatic ductal adenocarcinoma (PDAC), has been accepted for poster presentation at the European Society http://www.streetinsider.com/Globe+Newswire/Can-Fite+Positive+Phase+2a+Pancreatic+Cancer+Study+Data+Accepted+for+Presentation+at+ESMO+Congress+2026%2C+One+of+the+World%26apos%3Bs+Premier+Scientific+Meetings+in+Oncology/26786777.html Mon, 20 Jul 2026 07:00:00 -0400 CANF CANF CFBI O.05892622 http://www.streetinsider.com/Globe+Newswire/Can-Fite+Positive+Phase+2a+Pancreatic+Cancer+Study+Data+Accepted+for+Presentation+at+ESMO+Congress+2026%2C+One+of+the+World%26apos%3Bs+Premier+Scientific+Meetings+in+Oncology/26786777.html <p align="center"><i>Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months</i></p> <p align="justify">Ramat Gan, Israel, July 20, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ecGmRucGvgQw_lE8ggC3AtwdoLSsmzZMrvY98eDy9CL7-oZ0rRCR5Ig3DCCRYFStYQykbzv3zi67TJC79gANbtNXzEZGt2vseCkyKWdyeqQ=" rel="nofollow" target="_blank">Can-Fite BioPharma</a> Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that an abstract highlighting positive results from its Phase 2a study of Namodenoson in patients with advanced pancreatic ductal adenocarcinoma (PDAC), has been accepted for poster presentation at the European Society http://www.streetinsider.com/Globe+Newswire/Can-Fite+Positive+Phase+2a+Pancreatic+Cancer+Study+Data+Accepted+for+Presentation+at+ESMO+Congress+2026%2C+One+of+the+World%26apos%3Bs+Premier+Scientific+Meetings+in+Oncology/26786777.html Mon, 20 Jul 2026 07:00:00 -0400 CANF CANF CFBI O.05892622 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+Jul+14/26764726.html si-local-file:///var/storage/secattach/20260714/26764726.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+Jul+14/26764726.html Tue, 14 Jul 2026 07:12:00 -0400 CANF CANF O.05892622 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+Jul+14/26764726.html si-local-file:///var/storage/secattach/20260714/26764726.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+Jul+14/26764726.html Tue, 14 Jul 2026 07:12:00 -0400 CANF CANF O.05892622 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+Jul+14/26764726.html si-local-file:///var/storage/secattach/20260714/26764726.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+Jul+14/26764726.html Tue, 14 Jul 2026 07:12:00 -0400 CANF CANF O.05892622 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+Jul+06/26732596.html si-local-file:///var/storage/secattach/20260706/26732596.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+Jul+06/26732596.html Mon, 06 Jul 2026 07:03:00 -0400 CANF CANF O.05892622 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+Jul+06/26732596.html si-local-file:///var/storage/secattach/20260706/26732596.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+Jul+06/26732596.html Mon, 06 Jul 2026 07:03:00 -0400 CANF CANF O.05892622 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+Jul+06/26732596.html si-local-file:///var/storage/secattach/20260706/26732596.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+Jul+06/26732596.html Mon, 06 Jul 2026 07:03:00 -0400 CANF CANF O.05892622 http://www.streetinsider.com/Analyst+PT+Change/Can-Fite+BioPharma+%28CANF%29+PT+Raised+to+%248+at+H.C.+Wainwright/26723775.html (Updated - July 2, 2026 6:41 AM EDT) <p>H.C. Wainwright analyst Swayampakula Ramakanth raised the price target on Can-Fite BioPharma (NYSE: CANF) to $8.00 (from $5.00) while maintaining a Buy rating.</p><p>The analyst commented: "On July 1, 2026, Can-Fite reported that its open-label Phase 2a study evaluating namodenoson, an A3 adenosine receptor (A3AR) agonist, in advanced pancreatic ductal adenocarcinoma (PDAC) achieved its primary safety endpoint — consistent with the broader clinical evidence from other studies with more than 1,600 patients. The study enrolled 20 patients with advanced PDAC who had progressed on standard therapy. Enrolled patients were administered namodenoson as a monotherapy http://www.streetinsider.com/Analyst+PT+Change/Can-Fite+BioPharma+%28CANF%29+PT+Raised+to+%248+at+H.C.+Wainwright/26723775.html Thu, 02 Jul 2026 06:41:54 -0400 CANF http://www.streetinsider.com/Analyst+Comments/Can-Fite+BioPharma+%28CANF%29+PT+Raised+to+%248+at+H.C.+Wainwright/26723775.html (Updated - July 2, 2026 6:41 AM EDT) <p>H.C. Wainwright analyst Swayampakula Ramakanth raised the price target on Can-Fite BioPharma (NYSE: CANF) to $8.00 (from $5.00) while maintaining a Buy rating.</p><p>The analyst commented: "On July 1, 2026, Can-Fite reported that its open-label Phase 2a study evaluating namodenoson, an A3 adenosine receptor (A3AR) agonist, in advanced pancreatic ductal adenocarcinoma (PDAC) achieved its primary safety endpoint — consistent with the broader clinical evidence from other studies with more than 1,600 patients. The study enrolled 20 patients with advanced PDAC who had progressed on standard therapy. Enrolled patients were administered namodenoson as a monotherapy http://www.streetinsider.com/Analyst+Comments/Can-Fite+BioPharma+%28CANF%29+PT+Raised+to+%248+at+H.C.+Wainwright/26723775.html Thu, 02 Jul 2026 06:41:54 -0400 CANF http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+Jul+01/26716708.html si-local-file:///var/storage/secattach/20260701/26716708.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+Jul+01/26716708.html Wed, 01 Jul 2026 07:02:00 -0400 CANF CANF O.05892622 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+Jul+01/26716708.html si-local-file:///var/storage/secattach/20260701/26716708.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+Jul+01/26716708.html Wed, 01 Jul 2026 07:02:00 -0400 CANF CANF O.05892622 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+Jul+01/26716708.html si-local-file:///var/storage/secattach/20260701/26716708.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+Jul+01/26716708.html Wed, 01 Jul 2026 07:02:00 -0400 CANF CANF O.05892622